Drug

TQB3473 clinical trials

studies test it: 3
open now: 2
in phase 3: 1
first study started: 2020

How each study uses TQB3473 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the TQB3473 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

TQB3473 Tablets: 2

Development codes

TQB3473: 1

Studies by the year they started

3 studies that test it; most in 2025 (2)

Studies that test TQB3473, by start year
Year	Studies
2020	1
2025	2

By phase

A phase 1/2 study counts in both.

Phase 1: 1
Phase 2: 1
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Purpura, Thrombocytopenic, Idiopathic: 2
Hematologic Neoplasms: 1

Who runs them

Industry 3 · Other 0

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test TQB3473, phase 3 first.

Mar 2027A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune ThrombocytopeniaPhase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sep 2027A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in AdultsPhase 2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Studies

Open first, then newest update. How each study uses TQB3473 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.